vimarsana.com

Page 3 - அனைத்தும் இந்தியா நிறுவனங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Home secy Bhalla to review projects in J&K

Home secy Bhalla to review projects in J&K SECTIONS Last Updated: Jul 06, 2021, 07:59 AM IST Share Synopsis Several major road projects, two new All India Institutes of Medical Sciences and seven new medical colleges are being set up, according to the home ministry. Agencies Union home secretary Ajay Bhalla Union home secretary Ajay Kumar Bhalla will chair a meeting on Jammu and Kashmir on Tuesday where he is likely to review the Centre’s initiatives since the abrogation of Article 370 in August 2019 and examine the progress of projects in the Union Territory under the Prime Minister’s Development Package. Out of the total outlay of Rs 58,627 cr under the package, Rs 33, 331 cr has been released for development of the projects. Among other schemes, 90% utilisation has been achieved in individual beneficiary schemes in the Union Territory. Several major road projects, two new All India Institutes of Medical Sciences and seven new medical colleges are being set up, accordi

Revelan cómo de transmisible es Delta Plus

Revelan cómo de transmisible es Delta Plus Revelan cómo de transmisible es Delta Plus, la nueva y peligrosa variante del coronavirus. Científicos de la India están estudiando la nueva mutación para determinar si las vacunas existentes son efectivas contra ella o no. La nueva variante del covid-19 detectada recientemente en la India, denominada Delta Plus, es extremadamente transmisible e incluso caminar sin mascarilla junto a un paciente portador de esa cepa puede provocar la propagación de la misma, advirtió este martes Randeep Guleria, director de All India Institutes of Medical Sciences (AIIM), El experto explicó a India Today que, aunque seguir las recomendaciones para prevenir el covid-19 ayudará en gran medida contra esta nueva mutación, el Gobierno indio está preocupado por el mecanismo de escape inmunológico del Delta Plus y su resistencia a los anticuerpos monoclonales.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.